Literature DB >> 28235545

Clinical and neurocognitive aspects of hallucinations in Alzheimer's disease.

Mohamad El Haj1, Jean Roche2, Renaud Jardri3, Dimitrios Kapogiannis4, Karim Gallouj5, Pascal Antoine3.   

Abstract

Due to their prevalence, hallucinations are considered as one of the most frequent psychotic symptoms in Alzheimer's disease (AD). These psychotic manifestations reduce patients' well-being, increase the burden of caregivers, contribute to early institutionalization, and are related with the course of cognitive decline in AD. Considering their consequences, we provide a comprehensive account of the current state of knowledge about the prevalence and characteristics of hallucinations in AD. We propose a comprehensive and testable theoretical model about hallucinations in AD: the ALZHA (ALZheimer and HAllucinations) model. In this model, neurological, genetic, cognitive, affective, and iatrogenic factors associated with hallucinations in AD are highlighted. According to the ALZHA model, hallucinations in AD first involve trait markers (i.e., cognitive deficits, neurological deficits, genetic predisposition and/or sensory deficits) to which state markers that may trigger these experiences are added (e.g., psychological distress and/or iatrogenic factors). Finally, we provide recommendations for assessment and management of these psychotic manifestations in AD, with the aim to benefit patients, caregivers, and health professionals.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Clinical management; Hallucinations

Mesh:

Year:  2017        PMID: 28235545      PMCID: PMC5565710          DOI: 10.1016/j.neubiorev.2017.02.021

Source DB:  PubMed          Journal:  Neurosci Biobehav Rev        ISSN: 0149-7634            Impact factor:   8.989


  85 in total

1.  The neural basis of Charles Bonnet hallucinations: a hypothesis.

Authors:  W Burke
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-11       Impact factor: 10.154

Review 2.  Neuroimaging auditory hallucinations in schizophrenia: from neuroanatomy to neurochemistry and beyond.

Authors:  Paul Allen; Gemma Modinos; Daniela Hubl; Gregory Shields; Arnaud Cachia; Renaud Jardri; Pierre Thomas; Todd Woodward; Paul Shotbolt; Marion Plaze; Ralph Hoffman
Journal:  Schizophr Bull       Date:  2012-04-25       Impact factor: 9.306

3.  Neuropsychiatric symptoms underlying caregiver stress and insight in Alzheimer's disease.

Authors:  Paola Rocca; Daniela Leotta; Cesare Liffredo; Cinzia Mingrone; Monica Sigaudo; Barbara Capellero; Giuseppe Rocca; Mara Simoncini; Elvezio Pirfo; Filippo Bogetto
Journal:  Dement Geriatr Cogn Disord       Date:  2010-08-05       Impact factor: 2.959

4.  The omnipotence of voices. II: The Beliefs About Voices Questionnaire (BAVQ).

Authors:  P Chadwick; M Birchwood
Journal:  Br J Psychiatry       Date:  1995-06       Impact factor: 9.319

5.  Hallucinations, delusions, and cognitive decline in Alzheimer's disease.

Authors:  R S Wilson; D W Gilley; D A Bennett; L A Beckett; D A Evans
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-08       Impact factor: 10.154

6.  Spontaneous confabulators fail to suppress currently irrelevant memory traces.

Authors:  A Schnider; R Ptak
Journal:  Nat Neurosci       Date:  1999-07       Impact factor: 24.884

7.  Acute treatment of inpatients with psychotic symptoms using Acceptance and Commitment Therapy: pilot results.

Authors:  Brandon A Gaudiano; James D Herbert
Journal:  Behav Res Ther       Date:  2006-03

8.  Source monitoring in Alzheimer's disease.

Authors:  Mohamad El Haj; Luciano Fasotti; Philippe Allain
Journal:  Brain Cogn       Date:  2012-08-09       Impact factor: 2.310

9.  Hallucinations and conscious access to visual inputs in Parkinson's disease.

Authors:  Stéphanie Lefebvre; Guillaume Baille; Renaud Jardri; Lucie Plomhause; Sébastien Szaffarczyk; Luc Defebvre; Pierre Thomas; Christine Delmaire; Delphine Pins; Kathy Dujardin
Journal:  Sci Rep       Date:  2016-11-14       Impact factor: 4.379

10.  Apolipoprotein E epsilon4 allele increases risk for psychotic symptoms in Alzheimer's disease.

Authors:  Kristina F Zdanys; Timothy G Kleiman; Martha G MacAvoy; Benjamin T Black; Tracy E Rightmer; Monique Grey; Katherine S Garman; Rajesh R Tampi; Joel Gelernter; Christopher H van Dyck
Journal:  Neuropsychopharmacology       Date:  2006-07-12       Impact factor: 7.853

View more
  11 in total

1.  Hallucinations and Delusions Signal Alzheimer's Associated Cognitive Dysfunction More Strongly Compared to Other Neuropsychiatric Symptoms.

Authors:  Joshua T Fuller; Tabina K Choudhury; Deborah A Lowe; Steve Balsis
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2020-10-16       Impact factor: 4.077

2.  Predictors of Life Expectancy in Autopsy-Confirmed Alzheimer's Disease.

Authors:  Jeff Schaffert; Christian LoBue; Linda S Hynan; John Hart; Heidi Rossetti; Anne R Carlew; Laura Lacritz; Charles L White; C Munro Cullum
Journal:  J Alzheimers Dis       Date:  2022       Impact factor: 4.472

Review 3.  Psychosis in Alzheimer disease - mechanisms, genetics and therapeutic opportunities.

Authors:  Zahinoor Ismail; Byron Creese; Dag Aarsland; Helen C Kales; Constantine G Lyketsos; Robert A Sweet; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2022-01-04       Impact factor: 44.711

4.  Hallucinations and Covid-19: Increased Occurrence of Hallucinations in Patients with Alzheimer's Disease During Lockdown.

Authors:  Mohamad El Haj; Frank Larøi; Karim Gallouj
Journal:  Psychiatr Q       Date:  2021-06-05

Review 5.  The Use of Antipsychotic Drugs for Treating Behavioral Symptoms in Alzheimer's Disease.

Authors:  Valeria Calsolaro; Rachele Antognoli; Chukwuma Okoye; Fabio Monzani
Journal:  Front Pharmacol       Date:  2019-12-06       Impact factor: 5.810

6.  Hallucinations in a Patient with Alzheimer's Disease During the COVID-19 Crisis: A Case Study.

Authors:  Mohamad El Haj; Frank Larøi; Karim Gallouj
Journal:  J Alzheimers Dis Rep       Date:  2020-10-24

7.  Characteristics of Cortical Atrophy and White Matter Lesions Between Dementia With Lewy Bodies and Alzheimer's Disease: A Case-Control Study.

Authors:  Han Zhu; Hao Lu; Fei Wang; Shuai Liu; Zhihong Shi; Jinghuan Gan; Xiaoshan Du; Yaqi Yang; Daibin Li; Lichen Wang; Yong Ji
Journal:  Front Neurol       Date:  2022-01-11       Impact factor: 4.003

8.  Economic Evaluation of Healthcare Resource Utilization and Costs for Newly Diagnosed Dementia-Related Psychosis.

Authors:  Nazia Rashid; James B Wetmore; Muna Irfan; Victor Abler
Journal:  Geriatrics (Basel)       Date:  2022-03-08

9.  Understanding hallucinations in probable Alzheimer's disease: Very low prevalence rates in a tertiary memory clinic.

Authors:  Mascha M J Linszen; Afina W Lemstra; Meenakshi Dauwan; Rachel M Brouwer; Philip Scheltens; Iris E C Sommer
Journal:  Alzheimers Dement (Amst)       Date:  2018-04-21

10.  Use of Patient-Reported Symptoms from an Online Symptom Tracking Tool for Dementia Severity Staging: Development and Validation of a Machine Learning Approach.

Authors:  Aaqib Shehzad; Kenneth Rockwood; Justin Stanley; Taylor Dunn; Susan E Howlett
Journal:  J Med Internet Res       Date:  2020-11-11       Impact factor: 5.428

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.